Egyptian International Pharmaceutical Industries Company Stock

Equities

PHAR

EGS38081C013

Pharmaceuticals

End-of-day quote Egyptian Exchange 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
44.17 EGP +1.17% Intraday chart for Egyptian International Pharmaceutical Industries Company +1.17% +21.01%
Sales 2024 * 6.18B 128M Sales 2025 * 7.59B 157M Capitalization 6.57B 135M
Net income 2024 * 874M 18.02M Net income 2025 * 1.08B 22.37M EV / Sales 2024 * 1.9 x
Net Debt 2024 * 5.16B 106M Net Debt 2025 * 5.31B 110M EV / Sales 2025 * 1.57 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
3.96%
Yield 2025 *
5.66%
Free-Float 45.47%
More Fundamentals * Assessed data
Dynamic Chart
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Egyptian International Pharmaceutical Industries Company(CASE:PHAR) added to EGX 30 Index CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Medical Union Pharmaceuticals Company announced that it expects to receive funding from Egyptian International Pharmaceutical Industries Company and other investors CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Egyptian International Pharmaceutical Industries Company Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Egyptian International Pharmaceutical Industries Approves Cash Dividend for 2020 CI
Egyptian International Pharmaceutical Industries Company Appoints Ahmed Saeed Mohamed Kilany as the Company's Chairman and Managing Director CI
Egyptian International Pharmaceutical Industries Company's Equity Buyback announced on March 29, 2020, has expired. CI
More news
1 day+1.17%
1 week+1.17%
Current month-0.09%
1 month-8.93%
3 months+15.09%
6 months+23.41%
Current year+21.01%
More quotes
1 week
43.66
Extreme 43.66
44.37
1 month
42.51
Extreme 42.51
51.50
Current year
37.00
Extreme 37
53.49
1 year
24.50
Extreme 24.5
53.49
3 years
24.50
Extreme 24.5
53.49
5 years
24.50
Extreme 24.5
83.73
10 years
24.50
Extreme 24.5
122.40
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member - -
Chief Executive Officer - -
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-15 44.17 +1.17% 171,345
24-04-08 43.66 +0.95% 112,351

End-of-day quote Egyptian Exchange, April 14, 2024

More quotes
Egyptian International Pharmaceuticals Industries Co SAE (EIPICO) specializes in manufacturing and marketing pharmaceutical products. The products include primarily antibiotics, vitamins, anesthetics and analgesics, drugs for eye care, treatment of rheumatism, gout, gastrointestinal, dermatological and cardiovascular diseases, and are administered as capsules, gels and effervescent tablets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
44.17 EGP
Average target price
72.2 EGP
Spread / Average Target
+63.46%
Consensus

Chiffre d''affaires - Rate of surprise